The study, presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting, has made a groundbreaking discovery about the profound impact of weight-loss surgery on patients’ self-esteem. Researchers from Geisinger Medical Center found that within one year of undergoing bariatric surgery, participants experienced a staggering 131% increase in their self-esteem scores.

The study involved a database of 5,749 patients aged 18 and older with a body mass index (BMI) of 35 or more who had undergone metabolic and bariatric surgery between 2006 and 2019. The participants completed the Impact of Weight Quality of Life (iwQOL) survey before and 12 months after their operation to assess weight stigma and quality of life.

The results showed that self-esteem scores rose from an average of 33.6 to 77.5, a more than 40-point increase on a scale from 0 to 100. The study also found that the amount of weight loss was directly correlated with the increase in self-esteem, regardless of demographics such as gender, age, and race or type of bariatric procedure.

Justin Dhyani, MD, a co-author of the study, emphasized the importance of understanding weight stigma and psychosocial factors associated with obesity. “While these factors should not dictate the decision to have bariatric surgery, they should be an important part of the conversation,” he said.

Ann M. Rogers, MD, FACS, FASMBS, President of ASMBS, added that weight stigma is a serious issue that places an extra psychological burden on patients struggling with obesity. “This study shows we need to understand what patients are going through and be supportive and empowering of them as they navigate their health and make decisions about treatment,” she said.

The findings of this study have significant implications for the holistic care of patients with obesity, highlighting the importance of addressing weight stigma and psychosocial factors in conjunction with medical treatment. By providing supportive and empowering care, healthcare professionals can help patients achieve a better quality of life and overcome the challenges associated with obesity.

A groundbreaking clinical trial has revealed that a single dose of psilocybin, a naturally occurring psychedelic compound found in mushrooms, can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder. The findings, published in the peer-reviewed journal CANCER, suggest that this treatment approach may offer long-term relief for cancer patients struggling with depression.

The study involved 28 participants who received psychological support from a therapist prior to, during, and after receiving a single 25-mg dose of psilocybin. Two years later, a significant proportion of these individuals demonstrated lasting reductions in depression and anxiety. Specifically:

* 53.6% (15 patients) showed a sustained reduction in depression.
* 50% (14 patients) experienced remission from depression as well as reduced anxiety.
* 42.9% (12 patients) reported reduced anxiety at the two-year mark.

Building on these promising results, an ongoing randomized, double-blind trial is currently evaluating up to two doses of 25 mg of psilocybin versus placebo for treating depression and anxiety in cancer patients. This study aims to determine whether repeating the treatment can resolve depression for more than half of the participants.

According to lead author Manish Agrawal, MD, from Sunstone Therapies, “One dose of psilocybin with psychological support has a long-term positive impact on relieving depression for as much as 2 years for a substantial portion of patients with cancer. If randomized testing shows similar results, this could lead to greater use of psilocybin to treat depression in patients with cancer.”

Standardizing Psychedelic Research: A Breakthrough in Understanding the True Potential of Mind-Altering Drugs

The use of psychedelics as potential treatments for mental health disorders has gained significant traction in recent years. However, a critical flaw in psychedelic clinical trials has hindered their progress – the failure to properly account for how a person’s mindset and surroundings influence the effects of these substances.

A group of international researchers from McGill University, Imperial College London, and the University of Exeter have tackled this issue by developing a set of guidelines to standardize psychedelic clinical trials. The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines are a 30-item checklist that represents the first global agreement on which psychosocial factors have the greatest impact on a psychedelic experience.

“For decades, we’ve known that psychedelics don’t work in isolation,” said co-lead author Chloé Pronovost-Morgan. “The person’s mindset, the therapy room, even the music playing all influence outcomes.” This approach challenges the traditional way psychoactive drugs are typically studied, where scientists try to control or eliminate outside variables to isolate a drug’s effects.

These guidelines recognize that context is crucial and should be studied directly. By offering a standard framework for evaluating and reporting these variables, the ReSPCT guidelines aim to make trial outcomes more consistent and comparable across studies.

Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications,” said co-senior author Leor Roseman. “Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics.”

The lack of standards has had consequences beyond the research lab, Pronovost-Morgan explained. The U.S. Food and Drug Administration recently rejected MDMA-assisted therapy for post-traumatic stress disorder, citing inconsistent reporting across trials as a key reason for the decision.

“There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments,” said co-senior author Kyle Greenway. “Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most.”

The research team is organizing a three-day workshop in October, funded by McGill’s Healthy Brains, Healthy Lives initiative, where leading experts in psychedelics and neuroscience will discuss how the guidelines can be integrated into research and clinical practice.